who we are
About Us
As scientists and clinicians, we have dedicated our careers to an integrated approach to responding to disease and conditions driving adverse human health. With our understanding of the Microbiome, we have developed patented technology to disrupt the disease cascade of the myriad of diseases and health conditions strongly associated with the Human Microbiome.
Scaled Microbiomics has discovered solutions that can be rapidly and cost-effectively developed and deployed to address human health needs- providing diagnostics, prophylactics, and treatments to combat targeted conditions with our patented platform technology.
Mission
To protect and change society by leading the way in disease interception based on modulating microbiome signaling pathways and providing innovative therapeutics across a broad spectrum of disease states.
Value Proposition
Intercepting microbiome-driven disease and supporting wellness with targeted, passive immunotherapeutics that modulate microbiome-host signaling pathways through rational systems biology-based drug design.
About Us
As scientists and clinicians, we have dedicated our careers to an integrated approach to responding to disease and conditions driving adverse human health. With our understanding of the Microbiome, we have developed patented technology to disrupt the disease cascade of the myriad of diseases and health conditions strongly associated with the Human Microbiome.
Scaled Microbiomics has discovered solutions that can be rapidly and cost-effectively developed and deployed to address human health needs- providing diagnostics, prophylactics, and treatments to combat targeted conditions with our patented platform technology.
Mission
To protect and change society by leading the way in disease interception based on modulating microbiome signaling pathways and providing innovative therapeutics across a broad spectrum of disease states.
Value Proposition
Intercepting microbiome-driven disease and supporting wellness with targeted, passive immunotherapeutics that modulate microbiome-host signaling pathways through rational systems biology-based drug design.
Our Expertise
Our expertise lies in driving an antibody approach to Subtractive Microbiomic Therapies.
Our innovative approach combines an understood regulatory pathway (antibodies) with exciting new understanding of the microbiome manipulation to allow SMB to rapidly develop diagnostic and therapeutic interventions as an order of magnitude less time and cost.
We currently collaborate with academic experts in certain diseases and have developed a platform that can be efficiently directed at whatever target pathobiont is associated with microbiome dysbiosis and disease cascades.
Our Expertise
Our expertise lies in driving an antibody approach to Subtractive Microbiomic Therapies.
Our innovative approach combines an understood regulatory pathway (antibodies) with exciting new understanding of the microbiome manipulation to allow SMB to rapidly develop diagnostic and therapeutic interventions as an order of magnitude less time and cost.
We currently collaborate with academic experts in certain diseases and have developed a platform that can be efficiently directed at whatever target pathobiont is associated with microbiome dysbiosis and disease cascades.
Supplement Partners
SMB partners in the diagnostic and therapeutic sector, but can also offer high quality, low cost incredients to the supplement market. Our base material is GRAS (Generally Regarded as Safe) and by definition has an outstanding safety profile.
Supplement Partners
SMB partners in the diagnostic and therapeutic sector, but can also offer high quality, low cost incredients to the supplement market. Our base material is GRAS (Generally Regarded as Safe) and by definition has an outstanding safety profile.
Our Team
Brian Longstreet
Board Member
Stella Vnook
Board Member
Chris Daly, MHS
VP of Business Development
Julius Goepp, MD
Chief Scientific Officer
Mohamed Ait Ichou, PhD
Chief Scientific Officer in Lab
David Myers
Avian Agriculturalist
Brian Longstreet
Interim CEO
Stella Vnook
Board Member
Chris Daly, MHS
VP of Business Development
Julius Goepp, MD
Chief Scientific Officer
Mohamed Ait Ichou, PhD
Chief Scientific Officer in Lab
David Myers
Avian Agriculturalist
